Project Grant R21AI200424
- Federal Project Grant Award Summary Cedars-Sinai Medical Center received a $459,250 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), with an award date of June 20, 2025 and a completion date of May 31, 2027. The research initiative, titled "Synoviocyte Endothelial Cell Cross Talk in Rheumatoid Arthritis," investigates the mechanisms underlying fibroblast-like...
- Federal Project Grant Award Summary Cedars-Sinai Medical Center received a $740,319 Project Grant award dated June 10, 2026, from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award supports research investigation into TH17 cell plasticity in rheumatoid arthritis (RA), with a performance period extending through May 31, 2031. The research will produce scientific knowledge regarding the intrinsic and...
- Federal Project Grant Award Summary Cedars-Sinai Medical Center received a $879,906 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective June 20, 2025, with completion scheduled for May 31, 2027. This research project investigates the role of High Mobility Group Box 1 (HMGB1), a pro-inflammatory mediator, in the pathogenesis of Kawasaki Disease (KD) vasculitis using a...
- Federal Project Grant Award Summary Cedars-Sinai Medical Center received a $717,680 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded July 1, 2026, with completion targeted for March 31, 2029. The grant funds research to elucidate the immune epithelial niche underlying post-viral lung fibrosis, specifically investigating how persistent pulmonary fibrosis develops following severe viral respiratory...
- Federal Project Grant Award Summary Award Overview Cedars-Sinai Medical Center received a $300,000 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Trans-NIH Research Support program (CFDA 93.310) effective July 8, 2026, with a completion date of April 30, 2031. This award supports therapeutic preclinical development of TY1, a novel synthetic noncoding RNA (ncRNA) drug candidate designed to treat scleroderma-associated systemic sclerosis (SSC) cardiomyopathy....
- Federal Grant Award Summary Cedars-Sinai Medical Center received a $1.37 million Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) awarded August 15, 2025, with completion targeted for May 31, 2030. The award funds research investigating anti-Malassezia lipase antibodies (AMLAB) as a novel biomarker for inflammatory bowel disease (IBD), a dysregulated inflammatory...
- Federal Grant Award Summary Cedars-Sinai Medical Center received a $694,252 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 15, 2025, with completion targeted for June 30, 2030. The award funds research into the mechanisms of cardioprotective Y RNA (YRNA) signaling in macrophages to enhance therapeutic outcomes following myocardial infarction. The research focuses on understanding how a...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $464,750 to Icahn School of Medicine at Mount Sinai on July 7, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for a two-year project completion period extending through June 30, 2027. The award supports research focused on understanding and modulating T cell plasticity, specifically the transdifferentiation of TH17 cells into regulatory T cells...
- Federal Grant Award Summary Award Details: Cedars-Sinai Medical Center received a $1,214,851 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded August 20, 2025, with completion targeted for May 31, 2029. Research Scope and Deliverables: The grant funds investigation of nuclear transport mechanisms for SMAD signaling proteins, which are critical developmental effectors in left-right axis formation...
- Federal Project Grant Award Summary National Jewish Health received a $388,025 Project Grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), awarded June 1, 2026, with completion scheduled for May 31, 2028. The award funds the development of novel murine and human experimental models to elucidate the role of aberrant T cell subsets in systemic sclerosis-associated...
Cedars-Sinai Medical Center received a $256,650 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective July 2, 2026, with a completion date of June 30, 2028. The project, titled "ISG15 Monocytes as Precursors to SPP1 Macrophages in Scleroderma ILD," will deliver mechanistic research and biomarker discovery services focused on understanding systemic sclerosis (SSC) and associated interstitial lung disease (ILD). The research will investigate the role of peripheral classical monocyte subsets expressing ISG15, a type I interferon-response marker, and their potential differentiation into profibrotic macrophages expressing osteopontin (SPP1) in the lungs of SSC-ILD patients. The deliverables include translational research outputs comprising mechanistic investigations using human patient samples and the bleomycin-induced mouse model of SSC-ILD, biomarker discovery and validation studies, and analysis of monocyte/macrophage heterogeneity to inform disease characterization and progression prediction. Research findings are expected to support the refinement of macrophage-targeted therapeutic strategies and enhance clinical decision-making regarding disease stage and treatment selection. This project contributes to NIAID's broader mission of supporting biomedical research addressing infectious, immunologic, and allergic disease challenges through innovative approaches to improve public health outcomes.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $256.7k | 7/6/26 |